Results 51 to 60 of about 4,251 (181)

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

Therapeutic Advances in Medical Oncology
Background: There are no head-to-head studies comparing the efficacy of the Bruton tyrosine kinase inhibitors, zanubrutinib and acalabrutinib, in relapsed or refractory chronic lymphocytic leukemia (R/R CLL).
Mazyar Shadman, Jennifer R. Brown, Rhys Williams, Leyla Mohseninejad, Keri Yang, Pal Rakonczai, Nicole Lamanna, Sheng Xu, Aileen Cleary Cohen, Susan M. O’Brien, Alessandra Tedeschi, Constantine S. Tam   +11 more
doaj   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract We report primary analysis results from the Phase 3 PERSPECTIVE study comparing ibrutinib + rituximab versus placebo + rituximab in patients with previously untreated follicular lymphoma requiring treatment per Groupe d'Etude des Lymphomes Folliculaires criteria who were ineligible for chemoimmunotherapy due to age and/or comorbidities.
David Belada, Faithlore P. Gardner, Ana C. de Oliveira, Juan‐Manuel Sancho, Elza Lomaia, David Wright, Mehmet Turgut, Elena Martynova, Zsolt Lázár, Bertrand Anz, Ming‐Chung Wang, Wojciech Legiec, Stephen Opat, Junvie Pailden, Hillary M. Peltier, Emerenziana Marturano, James P. Dean, Ian W. Flinn   +17 more
wiley   +1 more source

Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

, 2021
Bruton tyrosine kinase (BTK) inhibition is an effective therapy for many B-cell malignancies. Acalabrutinib is a next-generation, potent, highly selective, covalent BTK inhibitor.
Owen, Roger G, Pagel, John M, Stephens, Deborah M., Streetly, Matthew J, Obrien, Susan M., Byrd, John C, Owen, Roger G., O\u27Brien, Susan M, Jurczak, Wojciech, Hamdy, Ahmed M, Furman, Richard R, Hillmen, Peter, Baek, Marshall, Pagel, John M., Furman, Richard R., Dyer, Martin J S, Stephens, Deborah M, Streetly, Matthew J., Sharman, Jeff P., Lezhava, Tamara, Patel, Priti, Sharman, Jeff P, Brown, Jennifer R, Christian, Beth, Dyer, Martin J. S., Sun, Clare, Chernyukhin, Nataliya, Brown, Jennifer R., Byrd, John C., Rule, Simon, Wang, Michael, Izumi, Raquel, Hamdy, Ahmed M., Ghia, Paolo   +33 more
core   +1 more source

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia.

, 2021
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). The efficacy and safety of acalabrutinib monotherapy was evaluated in a treatment-naïve CLL cohort of a single-arm phase 1/2 clinical trial ...
Jain, Nitin, O\u27Brien, Susan, Pagel, John M, Patel, Priti, Wierda, William George, Byrd, John C, Brown, Jennifer R, Wang, Min Hui, Woyach, Jennifer A, Furman, Richard R, Martin, Peter, Hillmen, Peter, Hamdy, Ahmed, Izumi, Raquel, Stephens, Deborah M, Barrientos, Jacqueline, Devereux, Stephen   +16 more
core  

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease

BMC Cancer, 2019
Background Transformation of chronic lymphocytic leukaemia (CLL) to diffuse large B-cell lymphoma (DLCBL) type Richter’s syndrome (RS) carries a dismal prognosis.
Niamh Appleby, Toby A. Eyre, Maite Cabes, Aimee Jackson, Rebecca Boucher, Francesca Yates, Sonia Fox, Andrew Rawstron, Peter Hillmen, Anna Schuh   +9 more
doaj   +1 more source

Expert Opinion on Managing Adverse Reactions Associated With Acalabrutinib Therapy: A Delphi Consensus From France

International audienceAcalabr utinib, a second-generation Br uton's tyrosine kinase inhibitor (BTKi), offers an improved safety profile compared to first-generation inhibitors like ibrutinib.
Ederhy, Stéphane, Leblond, Véronique, Malartre, Stéphanie, Sibaud, Vincent, Ysebaert, Loïc, Portalier, Anaïs, Zerbit, Jérémie, Tomowiak, Cécile   +7 more
core   +1 more source

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

BACKGROUNDWhether fixed-duration acalabrutinib-venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia (CLL) is unknown.METHODSIn this ...
Seymour, John F., Skarbnik, Alan, Eom, Ki-Seong, de Borja, Marianne, Wach, Malgorzata, Kater, Arnon Philip, Munugalavadla, Veerendra, Illes, Arpad, Brown, Jennifer R, Jurczak, Wojciech, Pavlovsky, Miguel Arturo, Miller, Kara, Brown, Jennifer R., Aw, Andrew, Simkovic, Martin, Lysak, Daniel, Owen, Carolyn, Tedeschi, Alessandra, Eichhorst, Barbara, Seymour, John F, Ghia, Paolo, AMPLIFY investigators, AMPLIFY investigators, Yu, Ting   +22 more
core   +1 more source

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice

Frontiers in Immunology, 2019
Sepsis is one of the most prevalent diseases in the world. The development of cardiac dysfunction in sepsis results in an increase of mortality. It is known that Bruton's tyrosine kinase (BTK) plays a role in toll-like receptor signaling and NLRP3 ...
Caroline E. O'Riordan, Gareth S. D. Purvis, Debora Collotta, Fausto Chiazza, Bianka Wissuwa, Bianka Wissuwa, Sura Al Zoubi, Lara Stiehler, Lara Stiehler, Lukas Martin, Lukas Martin, Sina M. Coldewey, Sina M. Coldewey, Massimo Collino, Christoph Thiemermann   +14 more
doaj   +1 more source

Acalabrutinib for mantle cell lymphoma [PDF]

Blood, 2019
AbstractMantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a
David Inwards, Thomas E. Witzig
openaire   +2 more sources